Results 71 to 80 of about 22,494 (197)

A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens

Cancer, Volume 131, Issue 21, 1 November 2025.
ABSTRACT Advances in the prognostication, monitoring, and treatment of both the acute and chronic leukemias have led to drastically improved outcomes over the past 2 decades. With the advent of targeted therapies, including antibodies such as blinatumomab and inotuzumab and small molecule inhibitors, such as the BCR::ABL1 tyrosine kinase inhibitors ...
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney DiNardo, Guillermo Garcia‐Manero, Ghayas Issa, Elias Jabbour, Nitin Jain, Tapan Kadia, Sanam Loghavi, Farhad Ravandi, Guilin Tang, Mary Alma Welch, William Wierda   +13 more
wiley   +1 more source

The Mechanisms of Imatinib Resistance in Gastrointestinal Stromal Tumours: Theoretical Basis and Therapeutic Aspect

Journal of Cellular and Molecular Medicine, Volume 29, Issue 21, November 2025.
ABSTRACT Imatinib is a small molecule that inhibits receptor tyrosine kinases KIT and platelet‐derived growth factor receptor α (PDGFRA). It was approved by the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of advanced, unresectable gastrointestinal stromal tumours (GISTs). Since then, additional kinase inhibitors targeting multiple
Nuerbiye Abudurexiti, Yidan Lou, Mengqi Wu, Yingchen Huang, Shan Huang, Kaibo Guo, Song Zheng   +6 more
wiley   +1 more source

Yttrium‐90 Selective Internal Radiotherapy for Gastrointestinal Stromal Tumor With Liver Metastasis: A Case Report and Review

Cancer Innovation, Volume 4, Issue 5, October 2025.
Therapeutic protocols are urgent for liver metastases in Gastrointestinal stromal tumors (GIST) patients. This article presents China's first case in GIST liver metastases patients, treating with Yttrium‐90 resin microsphere selective internal radiation therapy, reviews management challenges, and highlights the emerging role of novel therapies to ...
Li Xing, Xiaobin Feng, Lin Zhang, Zheng Mo, Zhuo Yu   +4 more
wiley   +1 more source

Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum‐Based Therapy

Head &Neck, Volume 47, Issue 10, Page 2735-2741, October 2025.
ABSTRACT Background Adenoid cystic carcinoma (ACC) is the second most common and treatment‐resistant salivary gland carcinoma (SGC). Although platinum‐based therapies are effective, the efficacy of eribulin, a microtubule inhibitor with an 18% response rate in a Phase II trial involving recurrent/metastatic SGC, in patients with advanced ACC after ...
Tomomi Sanomachi, Tatsunori Shimoi, Yuki Kojima, Hideaki Takahashi, Motoko Arakaki, Asuka Kawachi, Hitomi Sumiyoshi Okuma, Mai Hoshino, Munehiro Ito, Ayumi Saito, Shosuke Kita, Aiko Maejima, Tadaaki Nishikawa, Kazuki Sudo, Taisuke Mori, Yasuhiro Fujiwara, Kan Yonemori   +16 more
wiley   +1 more source

Predictive Analysis for First Submission of Generic Drug Application for Orphan Drug Products Using Random Survival Forest

Clinical and Translational Science, Volume 18, Issue 10, October 2025.
ABSTRACT Rare diseases affect a small population of patients, resulting in low incentives for developing orphan drug products (ODPs). The United States Congress passed the Orphan Drug Act of 1983 to incentivize pharmaceutical manufacturers to develop drugs to treat rare diseases.
Robert Hopefl, Jing Wang, Abhinav Ram Mohan, Wei‐Jhe Sun, Myong‐Jin Kim, Meng Hu, Lanyan Fang   +6 more
wiley   +1 more source

From fibro/adipogenic progenitors to adipocytes: Understanding adipogenesis in muscle degeneration for disease modulation

The Journal of Physiology, Volume 603, Issue 19, Page 5273-5297, October 1, 2025.
Abstract figure legend Fibro/adipogenic progenitors (FAPs) are cells resident in the muscle (skeletal and cardiac) niche. FAPs are active participants in the process of muscle degeneration in cardiovascular and neuromuscular diseases. Here, the accumulation of fatty and fibrous tissue is a hallmark.
Elisa Villalobos, Priyanka Mehra, Jordi Diaz‐Manera   +2 more
wiley   +1 more source

International Society for Prenatal Diagnosis 2024 Debate 3—Cytogenetics Is a Dinosaur and Should Be Replaced by Molecular Technologies

Prenatal Diagnosis, Volume 45, Issue 10, Page 1334-1342, September 2025.
ABSTRACT Cytogenetic technologies such as G‐banding chromosome and FISH analyses have long been the gold standard diagnostic test in prenatal genetic testing. However, unbiased next‐generation sequencing technologies such as fetal exome or genome sequencing (ES/GS) are becoming widely accessible and increasingly utilized, particularly for fetuses with ...
Yassmine M. N. Akkari, Michael E. Talkowski, Amy M. Breman   +2 more
wiley   +1 more source

Imatinib and hypophosphatemia: Case report and review of literature

Journal of Oncological Sciences, 2017
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated.
Erdem Şen, İrem Öner, Özlem Ata
doaj   +1 more source

Monitoring Twenty-Six Chronic Myeloid Leukemia Patients by BCR-ABL mRNA Level in Bone Marrow: A Single Hospital Experience [PDF]

, 2011
Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by
Akagi, Tomoaki, Kaimori, Mitsuomi, Kubo, Kohmei, Mariya, Yasushi, Ogura, Kazuto, Oshikiri, Toshiyuki, Sakamoto, Yuichi, Sasaki, Sumiko, Segawa, Megumi, Teshiromori, Ryuichi   +9 more
core   +1 more source

Imatinib decreases germ cell survival and germline stem cell proliferation in rodent testis ex vivo and in vitro

Andrology, Volume 13, Issue 6, Page 1575-1591, September 2025.
Abstract Background Imatinib and dasatinib are tyrosine kinase inhibitors (TKIs) increasingly used to treat several diseases in both children and adults at fertile age. We have previously shown that imatinib has adverse effects on developing testis, and imatinib‐treated male patients have been reported to have reduced sperm counts.
Anna Eggert, Sini Laasanen, Mirja Nurmio, Aida Wahlgren, Kirsi Jahnukainen, Kim Eerola, Miisael Nieminen, Opeyemi Olotu, Noora Kotaja, Juho‐Antti Mäkelä, Jorma Toppari   +10 more
wiley   +1 more source